Gegründet, um ein echtes Problem zu lösen.
Das EV-Feld hat außerordentliches Potenzial. Was gefehlt hat, ist Infrastruktur. Wir bauen sie auf.
Warum hat BioThera Solutions eine EV-Bioproduktionsplattform aufgebaut?
BioThera Solutions was founded to address a critical gap in the extracellular vesicle (EV/exosome) field: the absence of scalable, standardized, and reproducible manufacturing required to bring EV technologies of all kinds into real-world application. We set out to build that infrastructure as a platform, not a single product, and to lay the foundation for every application that comes after the first.
Trotz wachsender wissenschaftlicher Evidenz für EVs als potente biologische Abgabesysteme hat die Industrie Schwierigkeiten, Laborbefunde in kommerziell tragfähige, konsistent hergestellte Produkte zu übersetzen.
We are building that infrastructure, and we started where the need was most immediate. Interest in exosome-based skincare has grown quickly, driven by genuine scientific interest and consumer demand, yet the market is crowded with products making bold claims, backed by inadequate characterization, inconsistent particle concentrations, and little regulatory transparency. There is real demand, and a real absence of material that meets rigorous scientific standards.
BioThera was built to close that gap. We bring biomanufacturing expertise to a space that has been underserved by rigorous science: characterization in line with MISEV2023, measured particle concentrations, and documentation for every batch. Our research and development has produced proprietary, patent-pending technology and the capacity to manufacture at scale. For cosmetic applications, we license our technology exclusively to Vesera™, a skincare company, and produce the material it uses.
Cosmetic applications are where the platform first meets the market, and they are only the beginning. The infrastructure we are building, from manufacturing and characterization to the evidence base, is designed to carry across biological sources and applications. Our current platform uses plant-derived vesicles; as we grow, our research extends to animal-derived sources, including human stem cell-derived vesicles, and to therapeutic applications, an important focus for our team.
Build the integrated extracellular vesicle platform the field has been missing: standardized, characterized vesicles, engineered to work across biological sources, for applications that begin with cosmetics and extend well beyond them.
With cosmetic applications as our first commercial use, we are establishing the manufacturing infrastructure, characterization rigour, and evidence base that credible EV applications, including therapeutic ones, require.
To define what credible, science-led EV technology looks like, and to build the biomanufacturing backbone the extracellular vesicle field needs to mature, across every application it reaches.
We are in the early chapters of the EV era. Our ambition is to set the standard for the field by building the manufacturing foundation, characterization rigour, and evidence base that scientists, clinicians, partners, and regulators can trust.
Wofür wir stehen
Radikale wissenschaftliche Transparenz
Wir machen keine Aussagen, die wir nicht belegen können. Jede Produktspezifikation, jedes Charakterisierungsergebnis und jeder regulatorische Status wird präzise kommuniziert.
Kompromisslose Exzellenz
Herstellungsstandards, Charakterisierungsprotokolle, Formulierungsqualität, wir wenden auf jeder Stufe denselben Rigor an, unabhängig davon, wo wir uns im Entwicklungszyklus befinden.
Innovation
Der EV-Bereich ist früh. Die Herstellungsinfrastruktur, die EVs klinisch und kommerziell tragfähig macht, existiert noch nicht vollständig, wir bauen sie auf.
Ausführung
Ideen in der Biotechnologie sind reichlich. Rigorose, zuverlässige Ausführung ist selten. Wir schließen die Lücke zwischen wissenschaftlichem Potenzial und realer Bereitstellung.
Ottawa, Ontario, Kanada
BioThera Solutions hat seinen Hauptsitz in Ottawa, Ontario. Unser Standort bietet Nähe zu Regulierungsbehörden, einem wachsenden Life-Sciences-Ökosystem und den klinischen und Forschungspartnern, die zentral für unsere Arbeit sind.
477-150 Louis-Pasteur Private Ottawa, Ontario K1N 6N5 Canada
Universität Ottawa: STEM-Komplex · Ottawa, Ontario
Company Clarification
BioThera Solutions (Canada) is an independent biotechnology firm specializing in extracellular vesicle (EV) technology. We have no affiliation with Bio-Thera Solutions, Ltd. (China), which focuses on biosimilars and antibody-drug conjugates (ADCs). Our mission is to build the integrated platform that extracellular vesicle technology requires, from research and intellectual property to manufacturing, across the sources and applications of extracellular vesicles.
BioThera Solutions arbeitet ausschließlich mit ausgewählten Partnern.
Wir arbeiten gezielt mit Forschungs-, Klinik- und Industriepartnern zusammen, wenn eine starke wissenschaftliche und strategische Übereinstimmung besteht.
Partnerschaftsanfragen werden individuell geprüft.
Partnerschaft anfragenESG und Verantwortung
BioThera Solutions operates with environmental, social, and governance (ESG) principles built into how we work. Our current vesicles are derived from medicinal plants rather than animal or human tissue, and our biomanufacturing process is designed to be scalable and resource-efficient. We are transparent about our science and communicate clearly with clinical partners, suppliers, and the broader research community. Our governance practices are aligned with Health Canada cosmetic notification requirements, and our scientific reporting follows MISEV (Minimal Information for Studies of Extracellular Vesicles) guidelines. Sustainability and ethical conduct are part of how we build for the long term.